HR 'Significantly Better Than Expected' In Akeso's HARMONi-2 Trial in 1L NSCLC
Head-To-Head Study With Keytruda
Akeso's CEO has highlighted favorable hazard ratio results for the Chinese biotech's anti-PD-1/VEGF bispecific antibody ivonescimab in a head-to-head trial with Keytruda across Chinese NSCLC patients with positive PD-L1 expression in a first-line setting.
